Global CRISPR-Based Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB510234961

Publication Date:

October 9, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

CRISPR鈥恇ased genome editing technology has become an important potential therapeutic tool for various diseases.
The global CRISPR-Based Therapeutics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CRISPR-Based Therapeutics market research.
Key companies engaged in the CRISPR-Based Therapeutics industry include Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific and Horizon Discovery Group, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of CRISPR-Based Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CRISPR-Based Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CRISPR-Based Therapeutics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Caribou Biosciences
Addgene
CRISPR THERAPEUTICS
Merck KGaA
Mirus Bio LLC
Editas Medicine
Takara Bio USA
Thermo Fisher Scientific
Horizon Discovery Group
Intellia Therapeutics
GE Healthcare Dharmacon
Segment by Type
Genome Editing
Genetic Engineering
gRNA Database/Gene Librar
CRISPR Plasmid
Human Stem Cells
Genetically Modified Organisms/Crops
Cell Line Engineering
Segment by Application
Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research and Development Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CRISPR-Based Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global CRISPR-Based Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Genome Editing
1.2.3 Genetic Engineering
1.2.4 gRNA Database/Gene Librar
1.2.5 CRISPR Plasmid
1.2.6 Human Stem Cells
1.2.7 Genetically Modified Organisms/Crops
1.2.8 Cell Line Engineering
1.3 麻豆原创 by Application
1.3.1 Global CRISPR-Based Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Biotechnology Companies
1.3.3 Pharmaceutical Companies
1.3.4 Academic Institutes
1.3.5 Research and Development Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CRISPR-Based Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 CRISPR-Based Therapeutics Growth Trends by Region
2.2.1 Global CRISPR-Based Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 CRISPR-Based Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 CRISPR-Based Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 CRISPR-Based Therapeutics 麻豆原创 Dynamics
2.3.1 CRISPR-Based Therapeutics Industry Trends
2.3.2 CRISPR-Based Therapeutics 麻豆原创 Drivers
2.3.3 CRISPR-Based Therapeutics 麻豆原创 Challenges
2.3.4 CRISPR-Based Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top CRISPR-Based Therapeutics Players by Revenue
3.1.1 Global Top CRISPR-Based Therapeutics Players by Revenue (2018-2023)
3.1.2 Global CRISPR-Based Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global CRISPR-Based Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CRISPR-Based Therapeutics Revenue
3.4 Global CRISPR-Based Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global CRISPR-Based Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CRISPR-Based Therapeutics Revenue in 2022
3.5 CRISPR-Based Therapeutics Key Players Head office and Area Served
3.6 Key Players CRISPR-Based Therapeutics Product Solution and Service
3.7 Date of Enter into CRISPR-Based Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 CRISPR-Based Therapeutics Breakdown Data by Type
4.1 Global CRISPR-Based Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global CRISPR-Based Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 CRISPR-Based Therapeutics Breakdown Data by Application
5.1 Global CRISPR-Based Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global CRISPR-Based Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America CRISPR-Based Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America CRISPR-Based Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CRISPR-Based Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America CRISPR-Based Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CRISPR-Based Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe CRISPR-Based Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CRISPR-Based Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe CRISPR-Based Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CRISPR-Based Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific CRISPR-Based Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CRISPR-Based Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific CRISPR-Based Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CRISPR-Based Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America CRISPR-Based Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CRISPR-Based Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America CRISPR-Based Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CRISPR-Based Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa CRISPR-Based Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CRISPR-Based Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa CRISPR-Based Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Caribou Biosciences
11.1.1 Caribou Biosciences Company Detail
11.1.2 Caribou Biosciences Business Overview
11.1.3 Caribou Biosciences CRISPR-Based Therapeutics Introduction
11.1.4 Caribou Biosciences Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.1.5 Caribou Biosciences Recent Development
11.2 Addgene
11.2.1 Addgene Company Detail
11.2.2 Addgene Business Overview
11.2.3 Addgene CRISPR-Based Therapeutics Introduction
11.2.4 Addgene Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.2.5 Addgene Recent Development
11.3 CRISPR THERAPEUTICS
11.3.1 CRISPR THERAPEUTICS Company Detail
11.3.2 CRISPR THERAPEUTICS Business Overview
11.3.3 CRISPR THERAPEUTICS CRISPR-Based Therapeutics Introduction
11.3.4 CRISPR THERAPEUTICS Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.3.5 CRISPR THERAPEUTICS Recent Development
11.4 Merck KGaA
11.4.1 Merck KGaA Company Detail
11.4.2 Merck KGaA Business Overview
11.4.3 Merck KGaA CRISPR-Based Therapeutics Introduction
11.4.4 Merck KGaA Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.4.5 Merck KGaA Recent Development
11.5 Mirus Bio LLC
11.5.1 Mirus Bio LLC Company Detail
11.5.2 Mirus Bio LLC Business Overview
11.5.3 Mirus Bio LLC CRISPR-Based Therapeutics Introduction
11.5.4 Mirus Bio LLC Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.5.5 Mirus Bio LLC Recent Development
11.6 Editas Medicine
11.6.1 Editas Medicine Company Detail
11.6.2 Editas Medicine Business Overview
11.6.3 Editas Medicine CRISPR-Based Therapeutics Introduction
11.6.4 Editas Medicine Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.6.5 Editas Medicine Recent Development
11.7 Takara Bio USA
11.7.1 Takara Bio USA Company Detail
11.7.2 Takara Bio USA Business Overview
11.7.3 Takara Bio USA CRISPR-Based Therapeutics Introduction
11.7.4 Takara Bio USA Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.7.5 Takara Bio USA Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific CRISPR-Based Therapeutics Introduction
11.8.4 Thermo Fisher Scientific Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Horizon Discovery Group
11.9.1 Horizon Discovery Group Company Detail
11.9.2 Horizon Discovery Group Business Overview
11.9.3 Horizon Discovery Group CRISPR-Based Therapeutics Introduction
11.9.4 Horizon Discovery Group Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.9.5 Horizon Discovery Group Recent Development
11.10 Intellia Therapeutics
11.10.1 Intellia Therapeutics Company Detail
11.10.2 Intellia Therapeutics Business Overview
11.10.3 Intellia Therapeutics CRISPR-Based Therapeutics Introduction
11.10.4 Intellia Therapeutics Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.10.5 Intellia Therapeutics Recent Development
11.11 GE Healthcare Dharmacon
11.11.1 GE Healthcare Dharmacon Company Detail
11.11.2 GE Healthcare Dharmacon Business Overview
11.11.3 GE Healthcare Dharmacon CRISPR-Based Therapeutics Introduction
11.11.4 GE Healthcare Dharmacon Revenue in CRISPR-Based Therapeutics Business (2018-2023)
11.11.5 GE Healthcare Dharmacon Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Caribou Biosciences
Addgene
CRISPR THERAPEUTICS
Merck KGaA
Mirus Bio LLC
Editas Medicine
Takara Bio USA
Thermo Fisher Scientific
Horizon Discovery Group
Intellia Therapeutics
GE Healthcare Dharmacon

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.